AstraZeneca's stock dropped approximately 9.5% in London trading on Thursday, marking its steepest decline on the FTSE 100, after the company announced that its nerve disease treatment Wainua failed to meet the primary endpoint in a late-stage clinical trial for a serious heart condition. The setback undermines one of the drugmaker's most closely watched pipeline assets and raises questions about its broader growth strategy.
The Anglo-Swedish pharmaceutical giant, in partnership with U.S.-based Ionis Pharmaceuticals, reported that Wainua did not significantly reduce cardiovascular deaths or recurrent heart-related events in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). This progressive disease results from the accumulation of abnormal proteins in the heart, impairing its ability to pump blood and often leading to heart failure.
The disappointing outcome is a blow to AstraZeneca's ambitions to diversify beyond its core oncology business. The company has set a target of generating $80 billion in annual revenue by 2030 through the launch of up to 20 new medicines. Analysts had viewed the ATTR-CM indication as a crucial opportunity for Wainua to penetrate an underdeveloped market, with peak sales estimates reaching multi-billion dollars.
Trial Details and Subgroup Results
The phase-three CARDIO-TTRansform study enrolled 1,432 patients over 140 weeks, comparing Wainua added to standard treatment against placebo. The overall results showed no statistically significant benefit. However, subgroup analysis revealed mixed findings: among the 57% of participants already on stabilizer therapy at baseline, Wainua showed no measurable benefit. In contrast, patients receiving Wainua as a standalone treatment without stabilizers demonstrated a nominally significant benefit.
Sharon Barr, executive vice president of AstraZeneca's biopharmaceuticals R&D, stated: "Although the trial did not meet its primary objective, we believe the results support greater scientific understanding of treatment approaches for the hundreds of thousands of patients worldwide suffering from this progressive and often fatal condition." Wainua remains approved in over 20 countries for treating polyneuropathy, a rare neurological disorder, and generated $212 million in revenue for AstraZeneca in 2025.
Investor Sentiment and Pipeline Reassessment
The failed trial has prompted investors to reassess the company's near-term pipeline prospects. Citi, which maintains a Buy rating on AstraZeneca, had previously projected peak Wainua sales of around $6.2 billion in ATTR-CM, assigning a 59% probability of success. The bank estimated in May that failure of the CARDIO-TTRansform trial would reduce its discounted cash flow valuation by approximately 2.8%, or roughly £5.20 per share from its £181 fair value estimate.
At the time, Citi argued that the roughly 10% decline in AstraZeneca's stock from earlier highs had already more than reflected the combined downside risk from three key clinical trial readouts. The brokerage estimated a bear-case valuation of £168 per share even if all three major trials failed, still above where the stock traded then. The bullish scenario, assuming success across all three programmes, implied a valuation of about £204 per share.
Thursday's sharp sell-off suggests investors are attaching greater risk to AstraZeneca's remaining late-stage pipeline. Attention now turns to the upcoming SERENA-4 and AVANZAR trial results later this year, which could further influence the stock's trajectory. For context, similar market reactions have been seen in other sectors, such as Plug Power's 45% decline amid short interest concerns, highlighting how clinical or operational setbacks can rapidly shift investor sentiment.
As AstraZeneca navigates this setback, the broader market remains cautious. The company's ability to deliver on its ambitious revenue targets will depend on the success of its remaining pipeline candidates. Investors will be closely monitoring upcoming data readouts and any strategic adjustments from management.
This article is for informational purposes only and does not constitute financial advice.
